论文部分内容阅读
现行疗法中,非甾体类抗炎药因具有良好的镇痛抗炎和解热作用,是目前临床应用较多的风湿病治疗药。由于这类药物对胃粘膜的刺激很大,所以其使用受到很大的限制。近年来,药厂为降低其副作用,在几个方面进行了改进。 改变化学结构,降低不良反应:如济南金泰制药厂生产的非普拉宗片,是非甾体消炎、镇痛、解热新药,化学名称为4-戊烯基-1,2-二苯基-3,5-吡唑二酮,系保泰松的衍生物。保泰松因毒性较大,临床已被淘汰,而非普拉宗片是保泰松结构中的4-正丁基被4-戊烯基所取代的产物,药
The current therapy, non-steroidal anti-inflammatory drugs have a good analgesic anti-inflammatory and antipyretic effect, is currently more clinical applications of rheumatism medicine. Because of these drugs on gastric mucosa stimulation, so its use is greatly limited. In recent years, pharmaceutical companies to reduce their side effects, in several ways improved. Change the chemical structure, reduce adverse reactions: such as non-Polaroid films manufactured by Jinan Jintai Pharmaceutical Factory, which is a non-steroidal anti-inflammatory, analgesic and antipyretic drug whose chemical name is 4-pentenyl-1,2-diphenyl- 3,5-Pyrazolidinedione, a derivative of phenylbutazone. Phenylbutazone due to greater toxicity, clinical has been eliminated, but non-Pula Zongpian is phenylbutazone structure 4-n-butyl 4-pentenyl substituted products, drugs